Tomas J. Heyman
CIK 1814673 · last filed 2026-05-29
Tomas J. Heyman is a corporate insider who has filed 23 SEC Form 4 insider transactions across 6 companies since 2020. The most recent filing, for EXEL, was dated May 29, 2026. Across all open-market trades the lifetime net is −$1.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.69M
6
23
-$1.62M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EXEL | Director | 50,649 | $53.13 | $2.69M | -$201.3K | 5 | 2026-05-29 |
| Akero Therapeutics, Inc. (AKRO) Delisted | Director | 0 | $54.65 | $0 | -$1.42M | 8 | 2025-12-09 |
| OptiNose, Inc. (OPTN) Delisted | Director | — | $9.60 | — | $0 | 6 | 2025-05-21 |
| XLO | Director | — | $8.31 | — | $0 | 2 | 2023-06-13 |
| IVVD | Director | — | $0.77 | — | $0 | 1 | 2023-05-25 |
| Invivyd, Inc. (ADGI) Delisted | Director | — | $4.64 | — | $0 | 1 | 2022-06-24 |
Recent Filings
23 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-29 | EXEL | Grant (A) | +8,367 | $0 | EDGAR |
| 2025-12-09 | Akero Therapeutics, Inc. (AKRO) Delisted | Disp (D) | −9,398 | $0 | EDGAR |
| 2025-06-05 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | +9,398 | $0 | EDGAR |
| 2025-05-30 | EXEL | Grant (A) | +9,812 | $0 | EDGAR |
| 2025-05-22 | EXEL | Sell (S) | −4,544 | -$201.3K | EDGAR |
| 2025-05-21 | OptiNose, Inc. (OPTN) Delisted | Disp (D) | — | $0 | EDGAR |
| 2024-06-11 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | OptiNose, Inc. (OPTN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-04 | EXEL | Grant (A) | +18,838 | $0 | EDGAR |
| 2023-06-27 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | — | $0 | EDGAR |